ACE2 and COVID-19: Several promising outcomes have been reported after the transplantation of ACE2(-) MSCs in patients with COVID-19, including a decreased level of TNFα, an increase in peripheral lymphocytes, the disappearance of overactivated cytokine-secreting immune cells, and the improvement of the pulmonary function [15].